Quantum-Si Announces New Executive Team to Drive Company’s Growth in Proteomics
Quantum-Si Incorporated (Nasdaq: QSI), known as “The Protein Sequencing Company™,” has announced key leadership appointments. Effective September 17, 2024, Todd Bennett will join the company as the new Chief Commercial…
2024-2031 Analysis of Pharmaceutical Processing and Packaging Equipment Market Size, Share, Forecasts, and Trends
The new report, “Pharmaceutical Processing and Packaging Equipment Market: Size, Share, Forecast, and Trends Analysis by Formulation, Secondary Packaging, and End-of-Line Packaging – Global Forecast to 2031,” is now available…
Delcath Systems Reports Promising Study on Repeated Liver Chemosaturation
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), a leader in interventional oncology specializing in the treatment of primary and metastatic liver cancers, has announced the publication of an…
Ordspono (odronextamab) EU Approval for Treating Relapsed/Refractory Lymphomas
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that the European Commission (EC) has granted approval for Ordspono™ (odronextamab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)…
New Dupixent and Itepekimab Data at ERS Showcases Respiratory Innovation and Leadership
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that 20 abstracts related to Dupixent® (dupilumab) and the investigational therapy itepekimab will be presented at the European Respiratory Society (ERS) Congress 2024,…
Bristol Myers Squibb to Showcase Cardiovascular Portfolio Data at the European Society of Cardiology Congress 2024
Bristol Myers Squibb (NYSE: BMY) has announced that it will present research findings from its comprehensive cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, scheduled for August 30…
Invenra’s INV724 Gets FDA Rare Pediatric Disease and Orphan Drug Designations for Neuroblastoma
Invenra Inc. is excited to announce that its cutting-edge bispecific antibody, INV724, designed for neuroblastoma treatment, has received both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations from the…
ADVI Health Partners with Health Analytic Research for Acquisition
ADVI Health is excited to announce its acquisition of Partnership for Health Analytic Research (PHAR), a leading consultancy specializing in global health technology assessment (HTA) and health economics and outcomes…
Maria’s Journey: Navigating Life with a Rare Liver Disease
In 2017, Maria Morais began experiencing severe abdominal pain, which led to gall bladder surgery. However, when the procedure failed to alleviate her discomfort, follow-up tests revealed alarmingly high liver…
Aetna Contributes $100,000 to Support Safer Foundation
Aetna Better Health® of Illinois, a CVS Health® company (NYSE: CVS), has announced a generous community investment of $100,000 to the Safer Foundation. This funding aims to assist in housing…
GSK’s B7-H3 Antibody-Drug Conjugate Receives FDA Breakthrough Designation for Small-Cell Lung Cancer
GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to GSK5764227 (GSK’227), an investigational B7-H3-targeted antibody-drug conjugate (ADC) being studied…
Leqembi (lecanemab) Approved for Early Alzheimer’s Disease Treatment in Great Britain
Eisai Co., Ltd. (Tokyo, CEO: Haruo Naito) and Biogen Inc. (Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain…